Chester County News and Community Website
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has received clearance from the U.S. Food and Drug Administration (FDA) to begin a Phase 2/3 pivotal confirmatory trial of OCU410ST, an innovative …
Ocugen Receives FDA Clearance for Phase 2/3 Trial of Genetic Therapy for Stargardt Disease Read More
WILMINGTON, DE — First clinical data for INCA033989, a novel monoclonal antibody from Incyte (Nasdaq: INCY) targeting CALR-mutant myeloproliferative neoplasms (MPNs), were presented at the European Hematology Association (EHA) Congress …
Promising Results for Novel Therapy in CALR-Mutant Myeloproliferative Neoplasms Read More WILMINGTON, DE — Groundbreaking results from the Phase 3 POD1UM-303/InterAACT 2 trial have been published in The Lancet, showcasing the efficacy of retifanlimab (Zynyz®) in combination with carboplatin and paclitaxel …
New Phase 3 Trial Data Positions Retifanlimab as Breakthrough in Advanced SCAC Treatment Read More
PLYMOUTH MEETING, PA — A new study published in the June 2025 issue of JNCCN—Journal of the National Comprehensive Cancer Network highlights the life-changing impact of a telehealth-based care program …
Telehealth Program Improves Quality of Life for Older Cancer Patients, Study Finds Read More
BERWYN, PA — Panavance Therapeutics Inc. has shared promising interim findings from its ongoing Phase 1 clinical trial investigating misetionamide (GP-2250), a novel second-line therapy for advanced pancreatic cancer. These …
Panavance Therapeutics Reports Promising Phase 1 Results for Pancreatic Cancer Therapy Read More
EXTON, PA — Lungpacer Medical, Inc. has announced pivotal results from the RESCUE-3 trial, published in the American Journal of Respiratory and Critical Care Medicine, showcasing the groundbreaking benefits of …
Lungpacer Medical Publishes Landmark Findings on AeroPace System in Critical Care Read More
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has unveiled new clinical and translational data from its ongoing RESET-Myositis™, RESET-SLE™, and RESET-SSc™ trials. The findings highlight potential breakthroughs for rese-cel …
Cabaletta Bio Reports Promising Data from RESET Trials for Transformative Autoimmune Therapy Read More
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has received the initial proceeds from a prestigious FDA Orphan Products Development grant to support its ongoing Phase 3 SELVA trial of …
Palvella Therapeutics Secures FDA Grant Funding for Phase 3 Trial of QTORIN Rapamycin Read More
WILMINGTON, DE — The Phase III DESTINY-Breast09 clinical trial has delivered groundbreaking results, demonstrating that ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab significantly improves progression-free survival (PFS) for patients with HER2-positive metastatic …
ENHERTU plus Pertuzumab Shows Significant Progress in First-Line Treatment for HER2-Positive Breast Cancer Read More
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced a live webcast with Maria Maccecchini, Ph.D., President and CEO, to provide updates and answer audience questions.
Annovis Bio to Host Webcast on June 24, 2025, Featuring Updates on Phase 3 AD Trial and PD Program Development Read More